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rapidly from discovery to testing in the clinic. Hundreds
of stem cell clinical trials are estimated to be underway
for a wide range of conditions (Trounson et al., 2011,
2012). A 2013 Pharmaceutical Research andManufacturers
of America report lists nearly 80 industry-sponsored cell tri-
als under Food and Drug Administration review; 48 are
classified as stem cell trials, and 5 of these are in phase 3
(Pharmaceutical Research and Manufacturers of America
2013). In cardiovascular indications alone, over 100 studies
claiming stem cells as a modality are underway (National
Institutes of Health, 2014). Dozens of these cardiac trials
have already been completed (Zhang et al., 2014).
This robust translational push equates to thousands of
patients enrolled in stem cell trials, and many more thou-
sands of prospective participants inquiring about whether
they are eligible for new studies. As a result, Trounson
et al. (2012) warn that there is an urgent need for pro-
fessionally trained staff to objectively explain the risks
and benefits of stem cell transplants to prospective clinical
trial subjects and their families. These trained experts,
described here as stem cell counselors, could help po-
tential participants navigate among trials; explain risks,
benefits, and therapeutic alternatives; and provide infor-
mation about unproven transplants offered outside the
bounds of clinical research. Stem cell counselors would
also work closely with patients enrolled in clinical trials
and serve as a public resource for patient education and
outreach efforts.
This paper describes how a new counseling profession
could support clinical sites and patients enrolling in stem
cell clinical trials. A model is proposed, along with a curric-
ulum that would provide counselors with the tools to
address major issues facing the clinical stem cell field.
Finally, a candidate recruitment and clinical site interface
scheme is offered.
The Model: Genetic Counseling
Genetic counseling—which emerged out of advances in
human genetics—is a mature and successful example of a
client-centered approach to medical care. At its core, ge-
netic counseling provides information and support for peo-
ple who have or may be at risk for genetic disorders. While
genetic counseling began in pediatric/medical genetics and
prenatal diagnosis, these professionals now work in manyspecialty areas, including assisted reproductive tech-
nologies, noninvasive prenatal testing, cancer, cord blood
banking, cardiology, neurology, psychiatry, metabolic dis-
ease, and genomics/personalized medicine (Minkoff and
Berkowitz, 2014; Hendrick and Cobos, 2010). While these
subfields are guided by genetics and heritability, a principle
that finds resonance here is the acknowledgment that
counseling is a communication process with patient auton-
omy at its core. Other long-standing precepts include
knowledge of science, patient advocacy, respect for the
values of patients and families, and teaching and providing
information at a level appropriate to the patient’s under-
standing and interest. Collectively, these activities serve
to encourage context-rich, informed patient decisions (Na-
tional Society of Genetic Counselors, 2014). The National
Society of Genetic Counselors has recognized the im-
portance of stem cell trials in a recent position statement
outlining the different roles that genetic counselors can
play in stem cell research, including identifying appro-
priate research subjects and educating the public (Kirkpa-
trick et al., 2013). However, counselors with rigorous
training in stem cell sciences and related ethics, law, and
social implications (ELSI) disciplines would provide the
greatest benefit for patients and the public.
There are several models of genetic counseling that could
ably serve patients seeking stem cell transplants. In light
of the misinformation and hype surrounding stem cell
science, a teaching-based, information-centered method
would seem to have clear advantages. However, a strict
patient education model may fall short when considering
the ethical, social, and political complexities of stem cell
clinical trials. Instead, a nondirective, person-centered
model—developed by the psychologist Carl Rogers in the
1950s—would value the patient’s belief system, strive to
understand the patient’s experiences a larger social
context, and empower the patient to make independent,
informed definitions free from coercion (Veatch, 2003).
Taking this nondirective approach one step further, a bio-
psychosocial model—first proposed by George Engel—
would attend to the biological, psychological, and social di-
mensions of the illness. Adapted to stem cell trials, this
approach would integrate objective biomedical data along
with the patient’s subjective experience. In Engel’s scheme,
the goal is to transform the patient’s role from a passive
recipient of information to one of active, informed choiceStem Cell Reports j Vol. 4 j 1–6 j January 13, 2015 j ª2015 The Authors 1
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1977; Borrell-Carrio´ et al., 2004).
With these genetic counseling models in mind, stem cell
counselors would offer important advantages to individ-
uals seeking to enroll in trials and assistance to study per-
sonnel. They include communicating specialized patient
information, guarding against stem cell tourism, and
bolstering the process of informed consent and personal
autonomy.
Communicating Specialized Patient Information
Stem cell research organizations such as the International
Society for Stem Cell Research (ISSCR), the Stem Cell
Network of Canada, and the Australian Stem Cell Centre
have produced educational materials on websites to help
patients understand clinical trials, assess scientific evi-
dence, and identify possible rogue clinics (International So-
ciety for Stem Cell Research, 2014; Stem Cell Network of
Canada, 2014; National Stem Cell Foundation of Australia,
2013). These materials also highlight existing clinical trials
and successful research outcomes (Master and Ogbogu,
2012), but traditional types of patient outreach and educa-
tion efforts suffer from three limitations. First, the informa-
tion is often transmitted one way—from experts to pa-
tient—without knowing whether it has been effectively
communicated or whether it accounts for what patients
and families might find most valuable in their decision
making. Outreach ismost effective when it directly engages
individuals and respects values-based opinions and has
become an essential part of patient-centered outcomes
research (Patient-Centered Outcome Research Institute,
2014; Lensch, 2011; Murdoch and Scott, 2010). In addi-
tion, these materials encourage patients to consult with
their physicians for specific information about preclinical
studies, ethical oversight, and possible treatments. Profes-
sional responsibilities and legal obligations dictate that
physicians must help patients understand this informa-
tion, yet some physicians may not have the needed exper-
tise—or the time—to offer meaningful recommendations,
especially for those unproven stem cell interventions
offered outside the bounds of a clinical trial (Levine and
Wolf, 2012; Zarzeczny and Caulfield, 2010). Second, in a
fast-moving, fluid field, patient education materials can
quickly become outdated. Information may not reflect
the most recent clinical or preclinical evidence supporting
a study or fully detail the risks and benefits associated with
a specialized type of transplant. Finally, materials are often
generalized for broad audiences. Here, training in
bioethics, regulation, and social implications of stem cell
researchwould enrich communicationswith awide variety
of patients. Research subjects may have deeply held moral
views or have widely varying degrees of technical and sci-
entific understanding. They may need an advocate to2 Stem Cell Reports j Vol. 4 j 1–6 j January 13, 2015 j ª2015 The Authorshelp them interpret results, navigate the hospital system,
and ensure proper follow-up care. For example, some trials,
such as for autism or spinal cord injury, may be conducted
in charged and complicated sociopolitical environments.
Some patient populations will be more vulnerable than
others, and some may have different impressions of risk
and benefit (Liu and Scott, 2014; Scott and Magnus,
2014). Finally, the local context of clinical trials is critical
to meet local expectations, as fundamentally different
types of relationships exist between patients and re-
searchers (Hunt et al., 2005). As specific types of cells are
used to treat specific diseases, counseling information will
have to be current, accurate, and personalized.
Guarding Against Stem Cell ‘‘Tourism’’
As the advent of genetic counseling served to distance hu-
man genetics from eugenics, an argument can be made for
drawing a sharp boundary between ethical and unethical
clinical practice in regenerative medicine (Veatch, 2003).
Chief among these is the practice of traveling to receive
unproven stem cell interventions, often called stem cell
tourism (the common use of the term ‘‘stem cell tourism’’
is not generally preferred, although it continues to be
widely used in the literature). This is primarily an In-
ternet-based, direct-to-consumer marketed industry where
patients travel to destinations outside their home country
to receive untested and unproven clinical stem cell injec-
tions (Master and Resnik, 2013). One of the hallmarks of
stem cell tourism is a form of arbitrage, where a market of
clinics and patients—representing supply and demand—
are set up along permissive and restrictive regulatory gradi-
ents. As a result, clinics offering unproven treatments are
drawing unprecedented numbers of patients (Trounson
et al., 2012).
Seeking out unproven stem cell interventions is not
limited to international destinations. To varying degrees,
some transplant clinics in the United States and other juris-
dictions operate outside of regulation. In the United States,
patients may frequent unregulated clinics in other states or
within their own state. When it comes to guarding against
stem cell tourism, there is little reliable information for
potential patients on how the translational process ensures
the safety and efficacy of stem cell treatments (Master et al.,
2013). Disease advocacy groups lack good web-based
educational content about stem cell clinical translation,
and even scientific organizations have little information
onproven stem cell treatments, the clinical translation pro-
cess, and stem cell pseudomedicine (Master et al., 2014).
Without a clearinghouse for patient education, resulting
harms from stem cell tourism are sweeping and trouble-
some, including physical risk, erosion of public trust from
ineffective procedures, and failure to gain generalizable
knowledge. Undue burdens on health systems can result
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and incomplete or missing medical information (Crooks
et al., 2013). Patients who receive untested transplants
may be disqualified from legitimate trials. Patients who
travel may misperceive themselves as well-informed me-
dical pioneers who contribute to scientific knowledge
(Rachul, 2011). Indeed, as pediatric genetic counseling is
routinely used for many disorders, it is safe to assume
that parents will have understandable desires to help their
children in the stem cell setting. This means that physi-
cians and counselors must be guided by the best interests
ofminor patients, which include giving parents the best in-
formation possible about potential risks associated with
unproven treatments (Zarzeczny and Caulfield, 2010).
Understanding patientmotivations and perspectives will
be helpful in enabling autonomous choice. While it is true
that some patients who travel for untested therapies will
opt out of the medical system and thus bypass information
gained from a counseling encounter, a mature field of
credentialed professionals could become an important
and timely resource for education about unproven trans-
plants. Stem cell counselors, armed with current research
and trained in psychosocial methods that respect patient
beliefs and values, could help patients seeking therapies
gain a sense of control and facilitate informed decision
making—through the Internet or in person.
Bolstering Informed Consent and Patient Autonomy
In genetic counseling, enablement of autonomous deci-
sionmaking is considered a primary aim and respect for au-
tonomy is used to justify an approach whereby patients are
free to make their own choices after given all the necessary
information. Similarly, a code of ethics for stem cell coun-
selingwould require that counselors provide relevant infor-
mation for informed decision making while respecting
patient’s values and the social context of the trial. Together
with their families, patients usually join trials with a basic
understanding of the procedure; explanations of valid
data are needed to responsibly describe the benefits and
risks associated with a trial and compare stem cell interven-
tions with other alternatives (Sipp and Turner, 2012). Some
patients may need help navigating among competing tri-
als. Thus, enabling a process of informed consent would
be an essential part of a stem cell counselor’s repertoire.
Counselors would be trained in the ethical principles of
informed consent and personal autonomy, with the goal
of helping to bring a better informed volunteer to the
enrollment desk. An informed choice model of stem cell
counseling can offer ‘‘autonomy in relation,’’ where the pa-
tient and family can make fully informed decisions with
the stem cell counselor’s advice (Borrell-Carrio´ et al., 2004).
There are good reasons to conduct a counseling session
prior to enrollment in trials. Historically, the effectivenessof informed consents has been challenged, with the hype
and promise attached to stem cell treatments further
complicating whether participants truly understand the
risks associated with a particular trial (Appelbaum and
Lidz, 2008; Henderson 2011). Studies show that the pa-
tients’ ability to recall is usually poor (Flory and Emanuel,
2004), and the socioeconomic background and the envi-
ronment of the study participants can influence compre-
hension of information (Bowling and Ebrahim, 2001).
One way that a discussion of risks and benefits could be
facilitated is through a staged process, where a consent
document could bemailed to patients before their appoint-
ment and major questions could be fielded at the begin-
ning of the session. As consents for stem cell trials are likely
to contain variation about the types of cells transplanted,
routes of administration, patient populations, and dif-
fering risks and benefits, counseling sessions could greatly
enable informed decision making. The idea is not to pro-
vide informed consent in a counseling session, but to
help the patient make sense of the document—and the
risks and benefits—before they enroll in the trial.
What Would a Stem Cell Counseling Curriculum
Look Like?
Depending on the background and experience of appli-
cants, a 20–30 credit hour, certificate-based curriculum
would be sufficient to train students in specific core compe-
tencies. In contrast, a 40 credit-hour, 1-year master’s degree
program would include a research component and specific
training in certain disease areas. In either case, a curriculum
comprised of three integrated, disciplinary pillars would
include (1) basic and clinical sciences, (2) bioethics training
in ELSI, and (3) psychosocial techniques. The major topics
of instruction under these disciplines are summarized in
Table 1.
Scientific instruction would include introductions to
both basic and clinical stem cell science, including surveys
of recent translational research. Knowledge of key ELSI
issues would span research and clinical ethics and include
cell, gamete, and embryo donation and topics in bio-
banking. In order to properly advise prospective par-
ticipants, counselors must be knowledgeable of the key
regulatory frameworks, including national, state, and local
guidelines, and the international oversight of stem cell
transplants and clinics. A blended approach of instruction
would include online, didactic, and clinical pedagogies,
adapted from existing coursework atmajor research univer-
sities. Other instructional content would include virtual
journal clubs and clinical rounds for trainees. Faculty
supervisors and mentors would work individually with
trainees on directed readings and independent study. As
milestones for completed blocks of study, trainees would
be given intensive 2-day capstone programs in rapidlyStem Cell Reports j Vol. 4 j 1–6 j January 13, 2015 j ª2015 The Authors 3
Table 1. Major Disciplinary Pillars for Training Stem Cell
Counselors
Basic/Clinical
Science ELSI Psychosocial
Genetics and
epigenetics
responsible research
conduct
counseling and
communication techniques
Human
embryology
cloning and moral
status
underlying counseling
models
Cell and stem
cell biology
human-animal
chimeras
role-play training
Renewal embryo and tissue
donation
psychosocial techniques
Potency informed consent medical communication
Signal
transduction
therapeutic
misconception
assessing family dynamics
Lineage
restriction
stem cell tourism referrals to patient
networks
Cloning/
reprogramming
biobanking referrals to clinical experts
Translational
biology
privacy and return
of results
tourism hotlines/forums
Animal models equipoise cross-cultural competency
Cell processing risk/benefit working with interpreters
Transplant
biology
local, state, federal
law, and regulation
Clinical research protection of human
subjects
Trials design international
regulations & law
Enrollment clinical trials registries
Conducting trials
Patient advocacy
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give trainees the most current information about, for
example, regulation of stem cell tourism and review the lat-
est trials results for a given therapeutic area. Certificates or
degrees are time limited: continuing education would be
required in order to maintain certification. Recertifica-
tion—especially in a developing field—is critical to ensure
that counselors possess the most recent information and
may eventually become parts of licensure, professional
advancement, hospital credentialing, and insurance
reimbursement.
Stem cell counselors would require professional com-
petencies in the recruitment, enrollment, and conduct of
clinical trials. They should be able to critically evaluate sci-4 Stem Cell Reports j Vol. 4 j 1–6 j January 13, 2015 j ª2015 The Authorsentific and trials-based information in order to assist poten-
tial and enrolled participants with support services and
outreach programs. Even well-trained counselors will not
be able to stay abreast of every new clinical development,
and thus, an established society such as ISSCR or a national
network of clinician-scientists at enrolling sites could assist
counselors with specific client questions. The training
would focus on teamwork, professionalism, and strong
communication skills. Like their genetic counseling coun-
terparts, stem cell counselors should be able to conduct
client sessions to rigorously assess patient and family
needs, identify concerns, and help potential trials subjects
evaluate risks and benefits.
Admissions and Clinical Site Interface
In order to maximize the local expertise of clinical research
programs conducting stem cell trials and to ensure a seam-
less integration of counselors into the research stream, clin-
ical sites would put forward candidates for admission.
Future stem cell counselors are imagined to have existing
positions at sponsoring institutions and be allotted time
to conduct their training as clinical trials are being planned
or launched. Research institutions conducting trials would
employ certified stem cell counselors, but to avoid conflicts
of interest, counselors would not be supported directly by
individual trials.
A portfolio approach could guide the admissions process.
Instruction and credit-hour requirements would be tailored
for individuals with proven professional strengths in any of
the three core competencies. Nursing or social work profes-
sionals with strengths in clinical trialswould seem to bewell
suited to the program, as would trained genetic counselors
seeking to broaden their existing training. The curriculum
would be designed so that trainees could takemost of the in-
struction through self-paced online courses and blended in-
struction and would allow trainees to spend most of the
time in training at their home institution. An additional,
an intensive 2-week boot camp is also a potential model
for certification, one that has been successfully used in clin-
ical ethics training. Training could be augmented with vir-
tual best practices sessions and workshops.
Research: An Added Benefit
A credentialed program in stem cell counseling could offer
an important benefit to the stem cell field: research. Stem
cell counselors could employ social science and empirical
ethics approaches in ongoing research projects as part of
their professional development. Unique or especially chal-
lenging counseling sessions could form the basis of further
instruction through published case studies. Quantitative
research projects involving patient understanding of com-
plex medical information could inform outreach efforts
and the design of better informed consent. Data captured
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interactions with prospective trials participants can add
to the growing scholarship on the decisions patients
makewhen considering enrollment in a clinical trial. These
data could help health professionals and policy makers
understand what types of information patients use when
evaluating risks and benefit and identify gaps in knowledge
and misperceptions. Social science methodologies such as
grounded theory and content analysis would supply evi-
dence-based theoretical frameworks for a counseling prac-
tice (McAllister, 2001). Communicating across different
cultural and disability settings—including vulnerable pa-
tient populations—can be rigorously explored in a research
framework. A mature stem cell counseling field would
include a professional society, journals dedicated to the
discipline, and new centers of excellence. Institutions
that offer training would have the added benefit of a coun-
seling core for stem cell clinical trials and ongoing ELSI
research.
Challenges and Conclusions
The time is right for a credentialed stem cell counseling
training program. Admittedly, this will take the resources
and commitment of a research university with sufficient
field strength in the stem cell sciences. In early 2014, The
California Institute of Regenerative Medicine (CIRM)
announced plans to fund an educational and outreach
training (OET) program encompassing a stem cell coun-
seling training core for its ambitious Alpha Clinic transla-
tional medicine initiative. This would have established
the nation’s first counseling program to serve the agency’s
initial tranche of clinical trials based inCalifornia. Unfortu-
nately, CIRM restructured the Alpha Clinic initiative and
cancelled the OET program.
Without grant support to launch a stem cell counseling
discipline, universities conducting stem cell clinical trials
must consider how a credentialing program could fit with
the educational mission and how to support counselors
as trials increase. Genetic counseling salaries were initially
funded by a federal center grant and have slowly moved to
patient billing to cover part or all of the salaries. The ability
to bill and to be reimbursed was due to genetic counselors
becoming credentialed providers through payors; creden-
tialing was in turn influenced positively by state-based
licensure. Therefore, a sustainable profession must begin
with training and credentialing. Many genetic counselors
now cover salaries with a combination of clinical or hospi-
tal work and patient care. As most trials will be early phase
with low numbers of patients, initial caseloads (and associ-
ated costs) are expected to be low, but this raises challenges
for sites where the number of trials would not justify a full
time professional. As numbers of trials increase, institu-
tionally based counseling services could be built intodepartmental budgets. On the training side, with modest
investment and clear milestones, a certificate program
could grow to a degree-granting master’s level effort, with
tuition revenue for the host institution and wide-ranging
benefits to patients, clinicians, and the public.ACKNOWLEDGMENTS
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